Literature DB >> 23002022

Development and validation of a new disease activity index as a numerical sum of four variables in patients with early arthritis.

Isabel Castrejón1, Loreto Carmona, Ana M Ortiz, Miguel A Belmonte, Juan A Martínez-López, Isidoro González-Álvaro.   

Abstract

OBJECTIVE: To describe the development and validation of a disease activity index in early arthritis that can be easily applied in daily practice and clinical research.
METHODS: The Hospital Universitario La Princesa Index (HUPI) was developed after analysis of data from an early arthritis cohort (202 patients with 756 visits). It is the sum of 4 variables (graded 0-3): tender joint count, swollen joint count, patient global assessment, and acute-phase reactants (erythrocyte sedimentation rate [ESR] and/or C-reactive protein [CRP] level, depending on availability at the moment of evaluation). The score for each variable was based on its quartile distribution in the cohort. The HUPI was validated using the following properties: feasibility, internal consistency (Cronbach's alpha), convergent validity (Pearson's r coefficients with other activity measures), criterion validity (area under the receiver operating characteristic curve [AUC ROC] to detect minimal disease activity [MDA]), and sensitivity to change (AUC ROC) to detect change with the physician's and patient's assessment of disease activity.
RESULTS: Internal consistency is reasonable (α = 0.63). The HUPI correlates well with activity measures such as the Disease Activity Score in 28 joints (DAS28; r = 0.89) and the Simplified Disease Activity Index (SDAI; r = 0.70), and correlates slightly worse with the functional index of the Health Assessment Questionnaire (r = 0.69). It discriminates MDA correctly (AUC 0.95), and its sensitivity to change is slightly superior (AUC 0.902) to that of the DAS28-ESR (AUC 0.864), the DAS28-CRP (AUC 0.889), and the SDAI (AUC 0.791).
CONCLUSION: The HUPI has face validity, is easy to calculate, is sensitive, and is a valid composite index for the assessment of disease activity in patients with early arthritis, both in clinical research and in routine care.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2013        PMID: 23002022     DOI: 10.1002/acr.21854

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  8 in total

1.  Biologic therapy response and drug survival for females compared to males with rheumatoid arthritis: a cohort study.

Authors:  Jeffrey Lee; Randal Mason; Liam Martin; Cheryl Barnabe
Journal:  Rheumatol Int       Date:  2014-03-30       Impact factor: 2.631

2.  Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies.

Authors:  Michaela Koehm; Matthew J McIntosh; Michael W Hofmann; Varghese Abraham; Cem Gabay; Ernest H Choy; Arthur Kavanaugh; Harald Burkhardt; Frank Behrens
Journal:  Rheumatol Int       Date:  2020-02-10       Impact factor: 2.631

3.  Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies.

Authors:  Cristina Regueiro; Laura Nuño; Ana Triguero-Martinez; Ana M Ortiz; Alejandro Villalba; María Dolores Bóveda; Ana Martínez-Feito; Carmen Conde; Alejandro Balsa; Isidoro González-Alvaro; Antonio Gonzalez
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

4.  Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients.

Authors:  Irene Llorente; Leticia Merino; Ana M Ortiz; Eugenio Escolano; Saturnino González-Ortega; Rosario García-Vicuña; Jesús A García-Vadillo; Santos Castañeda; Isidoro González-Álvaro
Journal:  Rheumatol Int       Date:  2017-02-27       Impact factor: 2.631

5.  The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity.

Authors:  Isidoro González-Álvaro; Isabel Castrejón; Loreto Carmona
Journal:  PLoS One       Date:  2019-04-10       Impact factor: 3.240

Review 6.  Osteoporosis in Rheumatoid Arthritis: Dangerous Liaisons.

Authors:  Irene Llorente; Noelia García-Castañeda; Cristina Valero; Isidoro González-Álvaro; Santos Castañeda
Journal:  Front Med (Lausanne)       Date:  2020-11-23

Review 7.  Biomarkers predicting a need for intensive treatment in patients with early arthritis.

Authors:  I González-Álvaro; A M Ortiz; I V Seoane; R García-Vicuña; C Martínez; R P Gomariz
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

8.  Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis.

Authors:  Isidoro González-Álvaro; Isabel Castrejón; Ana M Ortiz; Esther Toledano; Santos Castañeda; Alberto García-Vadillo; Loreto Carmona
Journal:  PLoS One       Date:  2016-09-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.